Axel Boehnke is Director Market Access. He´s fully responsible all market access aspects, patient access as well early evidence planning as well as actions to accelerate access to patients, currently with the focus on orphan diseases and gene therapy. His experience in this area of work has allowed him to develop a sophisticated Market Access skill set. Axel has also in-depth knowledge and expertise in the specialized business, like Oncology, Autoimmune Diseases, (Ultra) Orphan Diseases, Hepatolgy, anti virals etc. He also has in depth experience in therapeutic mass markets like cardiovascular or Osteoporosis, with respective payer-interactions and contracting. He started with Humira at Abbott in national responsibility, headed the Department of Market Access and Managed Care at Servier, and served for experience in biohpharmaceutical industry for the last for years, mainly at Intercept responsible for Market Access, Pricing and Reimbursement in the DACH cluster. Before joining pharmaceutical industry 15 years ago, he worked at one of the biggest German Payers. He is Health Economist (University of Cologne) by education. In addition, he holds a master’s degree in health and medical management (University Erlangen-Nurnberg). Axel is a member of the German Society of Market Access and the German Society of Health Economics. He heads conferences on Market Access topics regarding HTA-assessment, evidence-framing, payer-engagement, pricing and Reimbursement. He published various articles on topics like benefit assessment, Market Access, Healthcare-system issues and disease awareness (i.e. in Rheumatoid Arthritis or Psoriasis), as well as on claims-data-analysis with Real World Evidence.